Athira Pharma, Inc. financial data

Symbol
ATHA on Nasdaq
Location
Bothell, WA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 631 % +45.8%
Debt-to-equity 19.1 % -36.3%
Return On Equity -107 % +7.41%
Return On Assets -89.9 % -1.06%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.94M shares -89.8%
Common Stock, Shares, Outstanding 3.94M shares -89.8%
Entity Public Float 86M USD -10.7%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 3.94M shares +2.39%
Weighted Average Number of Shares Outstanding, Diluted 3.94M shares +2.39%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 20.2M USD -76.3%
General and Administrative Expense 19.1M USD -28.9%
Costs and Expenses 39.3M USD -65.7%
Operating Income (Loss) -39.3M USD +65.7%
Net Income (Loss) Attributable to Parent -37.7M USD +65.5%
Earnings Per Share, Basic 4 USD/shares +77.5%
Earnings Per Share, Diluted 4 USD/shares +77.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.9M USD -69.7%
Assets, Current 27M USD -67%
Property, Plant and Equipment, Net 1.72M USD -36.2%
Operating Lease, Right-of-Use Asset 607K USD -30.3%
Other Assets, Noncurrent 55K USD 0%
Assets 30M USD -65.2%
Accounts Payable, Current 266K USD -31.4%
Employee-related Liabilities, Current 509K USD -88.5%
Accrued Liabilities, Current 2.07M USD -87.8%
Liabilities, Current 2.79M USD -90%
Operating Lease, Liability, Noncurrent 460K USD -49.6%
Liabilities 3.25M USD -88.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2K USD -167%
Retained Earnings (Accumulated Deficit) -429M USD -9.64%
Stockholders' Equity Attributable to Parent 26.8M USD -53.5%
Liabilities and Equity 30M USD -65.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.7M USD +43.2%
Net Cash Provided by (Used in) Financing Activities 99K USD -52.9%
Net Cash Provided by (Used in) Investing Activities -7.35M USD -156%
Common Stock, Shares Authorized 90M shares -90%
Common Stock, Shares, Issued 3.94M shares -89.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -22M USD -72.5%
Deferred Tax Assets, Valuation Allowance 91.9M USD +29.1%
Deferred Tax Assets, Gross 92.2M USD +28.5%
Operating Lease, Liability 912K USD -30.6%
Depreciation 971K USD +9.47%
Payments to Acquire Property, Plant, and Equipment 5K USD -97.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -37.7M USD +65.2%
Lessee, Operating Lease, Liability, to be Paid 981K USD -33.4%
Property, Plant and Equipment, Gross 5.74M USD 0%
Operating Lease, Liability, Current 452K USD +12.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 346K USD -32%
Lessee, Operating Lease, Liability, to be Paid, Year One 509K USD +3.04%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 69K USD -56.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 509K USD +3.04%
Deferred Tax Assets, Operating Loss Carryforwards 43.4M USD +38.5%
Unrecognized Tax Benefits 4.12M USD +32.6%
Deferred Tax Assets, Net of Valuation Allowance 25.2M USD +136%
Share-based Payment Arrangement, Expense 6.87M USD -37.8%